US equities |
INTC $66.14 ▼-28.16% AMZN $240.85 ▼-1.21% MU $889.02 ▼-4.84% NVDA $206.27 ▼-3.46% GOOGL $282.65 ▼-0.41% SNDK $1,189.96 ▼-10.53% SPCX $138.20 ▼-3.95% AMD $512.92 ▼-9.45%
FinancialContent

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

9.480 -0.225 (-2.32%)
Delayed Quote Updated: 11:26 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MeiraGTx Holdings plc - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Recap: MeiraGTx Hldgs Q4 Earnings ↗
 
Via Benzinga
News headline image
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of... 
From MeiraGTx
Via GlobeNewswire
News headline image
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
News headline image
MeiraGTx Hldgs: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today? ↗
MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson & Johnson (NYSE: JNJ) compan 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! 
Via InvestorPlace
News headline image
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Hldgs: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions
Best Growth Stocks, a leading independent research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a... 
Via TheNewswire.com
BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions
--News Direct-- 
Via News Direct
News headline image
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
News headline image
Why Is Gene Therapy Company MeiraGTx Stock Trading Higher Today? ↗
MeiraGTx Holdings plc (NASDAQ: MGTX) shares are trading higher after French pharma giant Sanofi SA (NASDAQ: SNY) made a $30 million  
Via Benzinga
News headline image
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Multiple Posters and Oral Presentations Highlight the Depth of Innovation from MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
RiboCAR-T cell activity can be precisely tuned and “remotely” controlled to improve the efficacy, durability and safety of CAR-T cell therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness ↗
MeiraGTx Holdings plc (NASDAQ: MGTX) released data from the completed Phase 1 AQUAx study of AAV2-hAQP1  for grade 2/3 radiation-induced xerostomia (RIX), which includes the final 12-month data from... 
Via Benzinga
News headline image
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,
From MeiraGTx
Via GlobeNewswire
News headline image
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
News headline image
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy 
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
From MeiraGTx
Via GlobeNewswire
< Previous 1 2 3 4 Next >